New Veeva Pulse findings show congresses and
early-career experts have the strongest influence on patient
outcomes
BARCELONA, Spain, July 25, 2024 /PRNewswire/ -- Veeva Systems
(NYSE: VEEV) today revealed that targeted pre-launch scientific
outreach maximizes medical affairs teams' impact on treatment
adoption in the latest Veeva Pulse Field Trends Report. The
analysis shows biopharmas investing in pre-launch scientific
activities and prioritizing congresses gain 40% faster treatment
adoption than those that invested less. Early-career experts are
also more open to digital engagement and four times more likely to
start patients on a new treatment.
Healthcare professionals (HCPs) are turning to biopharmas to
help distill rapidly evolving scientific evidence around new
innovative medicines and complex diseases. By focusing pre-launch
activity around clinical guidelines, publications, and congresses
with a new group of stakeholders, medical affairs teams can reach
key HCPs to improve treatment decisions.
"Gone are the days when medical could just focus on the top-tier
scientific thought leaders," said Angela
Smart, director of global medical excellence and operations
at ADVANZ PHARMA. "The range of stakeholders has broadened, and
it's imperative to expand our engagement strategies beyond
traditional experts."
The latest analysis from Veeva Pulse finds that:
- Targeted pre-launch scientific activities speed treatment
adoption: By engaging key experts at congresses, helping
develop clinical guidelines, and securing coverage in publications
before launch, companies see 40% faster treatment adoption than
those that invest less in this outreach. This demonstrates that
more resources for medical teams during this stage can boost launch
success.
- Congress activity has the strongest influence on clinical
decisions: Higher investment in pre-launch congress activities
has the most influence on treatment after approval. Congresses, and
the digital discussions that follow, help increase scientific
awareness and drive impactful medical conversations more than
investment in clinical guidelines and publications.
- Engaging early-career HCPs increases new treatment
uptake: These digitally-savvy emerging experts are four times
more likely to start patients on a new treatment. They are also
five times more likely to speak at congresses, 11 times more likely
to engage digitally, and seven times more likely to get
published.
"As HCPs gain an increasing amount of information to understand
complex new medicines across channels, effectively communicating
scientific evidence before launch can make all the difference,"
said Aaron Bean, vice president of
Veeva commercial business consulting, Europe. "By investing in
different types of scientific outreach and engaging newer experts
during this crucial window, medical teams can drive greater impact
and faster treatment adoption."
Companies can learn more about maximizing launch success
and the latest Veeva Pulse findings at Veeva Commercial
Summit Europe in Madrid,
November 19-21.
About the Veeva Pulse Field Trends Report
Analyzing
over 600 million HCP interactions and activities annually from more
than 80% of commercial biopharma field teams worldwide,
the Veeva Pulse Field Trends Report is the largest
industry benchmark of its kind on HCP engagement. The analysis
compiles real-time transactional data recorded in Veeva
CRM and Veeva data products to deliver a view of engagement
activity across life sciences. Indexed by Veeva quarterly, the data
will help companies effectively and accurately benchmark
performance to set the right, actionable goals for continued growth
and impact.
Additional Information
To download a copy of the Veeva
Pulse Field Trends Report, visit: veeva.com/eu/FieldTrends
Learn more about Veeva Business Consulting:
veeva.com/eu/BusinessConsulting
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information, visit
veeva.com/eu.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's
products and services and the expected results or benefits from use
of our products and services. These statements are based on our
current expectations. Actual results could differ materially from
those provided in this release and we have no obligation to update
such statements. There are numerous risks that have the potential
to negatively impact our results, including the risks and
uncertainties disclosed in our filing on Form 10-Q for the period
ended April 30, 2024, which you can
find here (a summary of risks which may impact our
business can be found on pages 35 and 36), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
Meera Lakhani-Patel
Veeva Systems
+44-790-430-0698
meera.lakhani-patel@veeva.com
Photo -
https://mma.prnewswire.com/media/2468846/Impact_of_Pre_launch_Graph.jpg
Photo -
https://mma.prnewswire.com/media/2468845/Channel_Influence_Graph.jpg
Logo -
https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/targeted-pre-launch-scientific-outreach-drives-40-faster-treatment-adoption-302206538.html